Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Celiac plexus block (CPB) is one of the main treatment options for patients resistant to conventional antihypertensive drugs. We present a case of resistant hypertension (RHTN) that was treated with CPB using botulinum toxin. An 18-year-old male patient with RHTN, who suffered from persistent hypertension even after combination therapy and a renal denervation procedure, was referred to our pain center for CPB. CPB using botulinum toxin following the use of only local anesthetics resulted in control of systolic blood pressure (BP) at ~150 mmHg for at least three months.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773804 | PMC |
| http://dx.doi.org/10.3390/toxins8020051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rac1 palmitoylation is required for cardiac stress adaptation and regulation of Protein Kinase A signaling.
JCI Insight
September 2025
Department of Pharmacology, University of Michigan, Ann Arbor, United States of America.
Cardiac hypertrophy is a common adaptation to cardiovascular stress and often a prelude to heart failure. We examined how S-palmitoylation of the small GTPase, Ras-related C3 botulinum toxin substrate 1 (Rac1), impacts cardiomyocyte stress signaling. Mutation of the cysteine-178 palmitoylation site impaired activation of Rac1 when overexpressed in cardiomyocytes.
View Article and Find Full Text PDFBotulinum toxin injection of the piriformis muscle for refractory pudendal neuralgia after decompression surgery: case report.
Pain Manag
September 2025
Serviço de Reabilitação de Adultos 3, Centro de Medicina de Reabilitação de Alcoitão, Alcabideche, Portugal.
Pudendal neuropathy is a cause of pelvic pain, specifically pudendal neuralgia. The pudendal nerve is related to sensory, motor, and autonomic functions. We present the case of a 41-year-old man who suffered from chronic pelvic pain.
View Article and Find Full Text PDFEfficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open-Label, Nonrandomized Controlled Trial.
Brain Behav
September 2025
Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Background And Purpose: Parkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX-A) in alleviating neuropsychiatric symptoms among PD patients.
Methods: This is an open-label, nonrandomized controlled trial.
Response to salivary gland botulinum toxin injection does not predict success from surgery for sialorrhoea (drooling) in children with neurodisability.
Eur J Pediatr
September 2025
Department of Paediatric Otolaryngology, Royal Hospital for Children, 1345 Govan Road, Glasgow, G51 4TF, UK.
Unlabelled: Drooling is a common problem in children with neurodisability, and refractory cases may require surgery. Our aim was to assess whether a child's response to salivary botulinum toxin injections would predict success or failure from subsequent surgical intervention. Retrospective case note review of all children undergoing drooling surgery between 1st January 2007 and 31st December 2023 at the Royal Hospital for Children, Glasgow.
View Article and Find Full Text PDFFACIAL SYMMETRY ENHANCEMENT AND BRAIN NETWORK MODIFICATIONS IN FACIAL PALSY PATIENTS AFTER BOTULINUM TOXIN TYPE A TREATMENT.
Plast Reconstr Surg
August 2025
Division of Plastic Surgery, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo - 05403-000, Brazil.